US2023285475A1PendingUtilityA1

Probiotic formulations and methods for use

Assignee: RES INST NATIONWIDE CHILDRENS HOSPITALPriority: Mar 6, 2014Filed: Aug 10, 2022Published: Sep 14, 2023
Est. expiryMar 6, 2034(~7.6 yrs left)· nominal 20-yr term from priority
A23L 33/135A61K 35/747A23V 2200/3202A23V 2200/3204A23L 33/195A23V 2002/00A61P 1/00A61P 1/02A61P 1/04A61P 11/02A61P 15/00A61P 17/00A61P 17/02A61P 25/00A61P 31/04A61P 37/02A61P 43/00A61K 9/1611A61K 9/1647A61K 9/1652A61K 9/1658
82
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Provided herein are compositions comprising a biocompatible microsphere, a biofilm-generating probiotic bacterium, a prebiotic, and/or a prebiofilmic. Methods for preparing and formulating the compositions and methods for treating or preventing a disease using the compositions are also provided.

Claims

exact text as granted — not AI-modified
1 - 61 . (canceled) 
     
     
         62 . A method of treating or alleviating depression or an anxiety disorder in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a composition comprising  Lactobacillus reuteri  (“ L. reuteri ”), a biocompatible microsphere, and a water-soluble carbohydrate, thereby treating or alleviating the depression or the anxiety disorder. 
     
     
         63 . The method of  claim 62 , wherein the  L. reuteri  is adhered to the biocompatible microsphere. 
     
     
         64 . The method of  claim 62 , wherein the  L. reuteri  is strain ATCC 23272. 
     
     
         65 . The method of  claim 62 , wherein the water-soluble carbohydrate is selected from the group consisting of maltose, sucrose, and combinations thereof. 
     
     
         66 . The method of  claim 62 , wherein the biocompatible microsphere has a diameter of about 1 micron to about 100 microns. 
     
     
         67 . The method of  claim 62 , wherein the subject also has a gastrointestinal disorder. 
     
     
         68 . The method of  claim 62 , wherein administration comprises an oral administration. 
     
     
         69 . The method of  claim 62 , wherein the composition is administered to provide from about 1×10 7  to about 1×10 9  CFU/ml of  L. reuteri.    
     
     
         70 . The method of  claim 62 , wherein the composition is administered in a single dose. 
     
     
         71 . The method of  claim 62 , wherein the composition is administered in multiple doses.

Join the waitlist — get patent alerts

Track US2023285475A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.